SCHEMBL23149238

SCHEMBL23149238

Cc1cc(Cl)ccc1NCCNC12CC(NC(=O)O)(C1)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ GAA P10253 5/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ EGFR P00533 1/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ MAPT P10636 3/20 0.37
▸ TDP1 Q9NUW8 2/20 0.37
▸ NOX1 Q9Y5S8 1/20 0.37
▸ CDC7 O00311 1/20 0.37
▸ EEF2K O00418 1/20 0.37
▸ PLK4 O00444 1/20 0.37
▸ AURKA O14965 1/20 0.37
▸ PDPK1 O15530 1/20 0.37
▸ DAPK3 O43293 1/20 0.37
▸ DYRK3 O43781 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23182886 0.85 DPP8 (0.37) KMT2AMEN1ALDH1A1GAAMAPT
SCHEMBL23149113 0.80 ATF4 (0.43) KMT2AMEN1ALDH1A1GAANPC1
SCHEMBL6118251 0.70 MAPK1 (0.63) KMT2AMEN1ALDH1A1GAAL3MBTL1
SCHEMBL14000123 0.69 GAA (0.49) KMT2AMEN1ALDH1A1GAAL3MBTL1
SCHEMBL23182885 0.68 SMN1; SMN2 (0.47) KMT2AMEN1ALDH1A1GAAL3MBTL1
SCHEMBL11246752 0.68 SMN1; SMN2 (0.59) KMT2AMEN1ALDH1A1GAAMAPK1
SCHEMBL23358860 0.68 ERCC5 (0.45) KMT2AMEN1ALDH1A1L3MBTL1NPC1
SCHEMBL7655772 0.68 SMN1; SMN2 (0.48) KMT2AMEN1ALDH1A1GAAMAPK1
SCHEMBL7655919 0.68 FERMT2 (0.52) GAASMN1; SMN2MAPTNOX1
SCHEMBL18622660 0.67 FERMT2 (0.50) ALDH1A1GAAMAPK1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210093619-A1 Chemical Compounds as ATF-4 Pathway Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210093619-A1 Chemical Compounds as ATF-4 Pathway Inhibitors ATF4, ATF1, XBP1 KMT2A 2770/4885MEN1 4697/4885ALDH1A1 2325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback